Saturday 27 December 2014
 
»
Tag
 
»
Eisai

Firm to market breast cancer drug in ME

Japan-based Eisai will market its breast cancer treatment Halaven (eribulin) in selected countries within the Middle East region through a new partnership between Eisai EMEA and NewBridge Pharmaceuticals. Eribulin is indicated for

More…

Eisai's breast cancer drug ‘extends lives’

Eisai's experimental breast cancer drug eribulin added an average of two and a half months to the lives of patients dying of breast cancer, which is a big improvement in such seriously ill cancer patients, researchers said. The results of

More…
 1 2 3 4 5 >  Last ›

calendarCalendar of Events

Ads